Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14994846rdf:typepubmed:Citationlld:pubmed
pubmed-article:14994846lifeskim:mentionsumls-concept:C0004238lld:lifeskim
pubmed-article:14994846lifeskim:mentionsumls-concept:C0489879lld:lifeskim
pubmed-article:14994846lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:14994846pubmed:issue1lld:pubmed
pubmed-article:14994846pubmed:dateCreated2004-3-3lld:pubmed
pubmed-article:14994846pubmed:abstractTextTo control ventricular rate in patients with AF, physicians should seek to control heart rate at rest and with exertion. The goal has to be achieved while minimizing costs and adverse effects. For emergency use, i.v. diltiazem or esmolol are drugs useful because of their rapid onset of action. They have to be used with caution in patients with concomitant left ventricular failure symptoms, however. For most patients with AF, chronic control of the ventricular rate can be achieved with one drug. For the chronic control of ventricular rate in patients with AF and normal ventricular function, diltiazem, atenolol, are metoprolol are probably the drugs of choice. For patients with AF and structurally abnormal hearts, atenolol, metoprolol, or carvedilol are appropriate choices. Adequate ventricular rate control by pharmacological agents should be evaluated by either 24-hour Holter monitoring or a submaximal stress test to determine the resting and exercise ventricular rate. If the mean ventricular rate is not close to 80 beats per minute, or the heart rate on moderate exertion is not between 90 to 115 beats per minute, a second agent to control the rate should be added. Excessive reductions in ventricular rates that could limit exercise tolerance should be avoided.lld:pubmed
pubmed-article:14994846pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14994846pubmed:languageenglld:pubmed
pubmed-article:14994846pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14994846pubmed:citationSubsetIMlld:pubmed
pubmed-article:14994846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14994846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14994846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14994846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14994846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14994846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14994846pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14994846pubmed:statusMEDLINElld:pubmed
pubmed-article:14994846pubmed:monthFeblld:pubmed
pubmed-article:14994846pubmed:issn0733-8651lld:pubmed
pubmed-article:14994846pubmed:authorpubmed-author:BassEric BEBlld:pubmed
pubmed-article:14994846pubmed:authorpubmed-author:TamarizLeonar...lld:pubmed
pubmed-article:14994846pubmed:issnTypePrintlld:pubmed
pubmed-article:14994846pubmed:volume22lld:pubmed
pubmed-article:14994846pubmed:ownerNLMlld:pubmed
pubmed-article:14994846pubmed:authorsCompleteYlld:pubmed
pubmed-article:14994846pubmed:pagination35-45lld:pubmed
pubmed-article:14994846pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:14994846pubmed:meshHeadingpubmed-meshheading:14994846...lld:pubmed
pubmed-article:14994846pubmed:meshHeadingpubmed-meshheading:14994846...lld:pubmed
pubmed-article:14994846pubmed:meshHeadingpubmed-meshheading:14994846...lld:pubmed
pubmed-article:14994846pubmed:meshHeadingpubmed-meshheading:14994846...lld:pubmed
pubmed-article:14994846pubmed:meshHeadingpubmed-meshheading:14994846...lld:pubmed
pubmed-article:14994846pubmed:meshHeadingpubmed-meshheading:14994846...lld:pubmed
pubmed-article:14994846pubmed:meshHeadingpubmed-meshheading:14994846...lld:pubmed
pubmed-article:14994846pubmed:meshHeadingpubmed-meshheading:14994846...lld:pubmed
pubmed-article:14994846pubmed:meshHeadingpubmed-meshheading:14994846...lld:pubmed
pubmed-article:14994846pubmed:meshHeadingpubmed-meshheading:14994846...lld:pubmed
pubmed-article:14994846pubmed:meshHeadingpubmed-meshheading:14994846...lld:pubmed
pubmed-article:14994846pubmed:year2004lld:pubmed
pubmed-article:14994846pubmed:articleTitlePharmacological rate control of atrial fibrillation.lld:pubmed
pubmed-article:14994846pubmed:affiliationDivision of General Internal Medicine, Johns Hopkins University, Welch Center for Prevention, Epidemiology and Clinical Research, 2024 East Monument Street, Room 2-516, Baltimore, MD 21205, USA. ltamari1@jhmi.edulld:pubmed
pubmed-article:14994846pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14994846pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:14994846pubmed:publicationTypeReviewlld:pubmed